Pharmaceutical filing citing a Neurology paper — Catalyst Pharmaceuticals, 2024-02-21
Catalyst PharmaceuticalsCatalyst PharmaceuticalsUS CPRX
cited a paper published in Neurology as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way it wrote the paper and the actual scope of the paper in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers of the document filed by Catalyst Pharmaceuticals on 2024-02-21 were 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Neurology in the attached press release. The sentence citing the paper, copied verbatim from the original, is as follows.
This study [VISION-DMD] was conducted to determine the efficacy and safety of vamorolone over 48 weeks and to study crossover participants (prednisone to vamorolone; placebo to vamorolone). A total of 121 participants with DMD were randomized.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the company's entire claim or only part of it. To answer the latter question, one must read the full paper. This article, which only read the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract is limited to this.
The paper's title is Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy and it was published in Neurology on 2024-02-09. The authors are affiliated with Veterans Affairs Canada. The summary at the beginning of the paper is called Abstract. This article only read up to there. The paragraph was written by a person after filtering a draft generated by a machine reading the abstract through numerical comparison, and thus differs in quality from a full-text review.
This is a 48-week trial of baricitinib in two doses for a young boy with Duchenne muscular dystrophy, aimed at reducing the side effects of steroids. The first half included a group receiving prednisone and a placebo group, while the second half continued entirely with baricitinib. This paper discusses the second half. Children who switched from placebo to high dose showed rapid improvement in motor function, while those who switched from prednisone showed varying degrees of improvement depending on the indicators. Safety was assessed together with growth rate and bone markers, and the data are in the main text.
The abstract does not answer; it remains in the main text and the appendix. This text, which does not go there, leaves the blank as it is. Readers compare the two citations above to determine which sentence in the abstract corresponds to the excerpt cited by the company.
One month later, the stock price was within the top quarter of the sample.
The return remaining after subtracting the portion that moves with the entire market is called excess return. The date is written as trading day, counting only the days the stock market is open. In terms of a calendar, 20 trading days are about a month. The regulatory filing day in this case and the excess return for the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | +0.4% | The extent to which the stock had already moved before the filing |
| regulatory filing day | −0.1% | filing day or the first trading day thereafter |
| +1~+5 trading day cumulative | +3.9% | one week |
| +1~+20 trading day cumulative | +16.8% | one month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +16.8% in this case is in the top quarter, corresponding to the 87% position from the bottom among 142 samples.
| sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | this case |
|---|---|---|---|---|---|---|
| excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +16.8% |
Half of the sample falls between the two middle marks in the table. Check the table to see whether this case falls inside or outside of that range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules to apply to future cases.
Another example of the same company reporting a paper in an 8-K filing is included in the sample and presented in the table below.
| Filing date | The journal of the reported paper | Excess return for one month |
|---|---|---|
| 2024-03-13 | Neurology | −6.6% |
After the filing, the company issued this document
Three 8-K filings issued by the company after the filing date are listed with only item numbers. In 8-K filings without titles, item numbers indicate the type of content, so it is possible to determine whether it was an earnings announcement or a contract. The specific event must be read in the original text of each link.
- 2024-02-29 8-K Item 8.01,9.01 — Other Events · Financial Statements and Exhibits
- 2024-03-13 8-K Item 8.01,9.01 — Other Events · Financial Statements and Exhibits
- 2024-05-08 8-K Item 8.01, 9.01 — Other Events · Financial Statements · Exhibits
What This Article Does Not Answer
This article, which reads only abstracts, cannot answer how the paper reviewed what methods, what it re-examined, and to what extent it showed results. How often the paper cited by the company was cited afterward can be rechecked through the citation count on OpenAlexOpenAlex
Data source · Website. What will be seen next is whether the company's next 8-K again cites the same paper.
Glossary
- 8-K
- A voluntary report submitted to the U.S. Securities and Exchange Commission when a listed company has something to inform shareholders. It is categorized by item numbers such as earnings, contracts, and executive changes. All the events in this article come from this document.
- Excess Return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement unique to the company by removing the portion where the market as a whole rose or fell.
- Trading day
- A count of days when the stock market is open. As weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, details and limitations of the method cannot be known.